Atlas Trials

Pyrotinib Rechallenge in Her2-positive Metastatic Breast Cancer Pretreated With Pyrotinib and Trastuzumab

Clinical trial NCT05346861 · UNKNOWN

Trial details

NCT number
NCT05346861
Sponsor
Fudan University
Status
UNKNOWN
Phase
Phase 3
Study type
INTERVENTIONAL
HER2-positive Breast CancerMetastatic Breast Cancer
Start date
2021-09-15
Primary completion
2023-10-31
Enrollment
240

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.